Chimeric Therapeutics has ticked off a new milestone in its battle against an aggressive cancer called “glioblastoma” after the successful completion of a second dose cohort program in a phase 1 dose escalation study at a renowned cancer centre near Los Angeles. The company says all patients dosed as part of the trial have now advanced past the 28 day follow-up period without experiencing…
